BlackRock, Inc. Amendment to Schedule 13G for Tourmaline Bio, Inc.

BlackRock, Inc. filed an amendment to its Schedule 13G for Tourmaline Bio, Inc., reporting a decrease in its ownership stake. As of September 30, 2025, BlackRock owns 1,411,832 shares, representing 5.5% of the common stock, down from the previous filing. The shares are held by various business units of BlackRock, and no single entity owns more than 5% of the total outstanding shares. The filing includes certifications that the shares were acquired and are held in the ordinary course of business, not for the purpose of influencing control of the issuer.